The University of
Nottingham

UNITED KINGDOM · CHINA · MALAYSIA

Choy, Kwok H.C. and Shackleford, David M. and Malone, Daniel T. and Mistry, Shailesh N. and Patil, Rahul T. and Scammells, Peter J. and Langmead, Christopher J. and Pantelis, Christos and Sexton, Patrick M. and Lane, Jonathan R. and Christopoulos, Arthur (2016) Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior. Journal of Pharmacology and Experimental Therapeutics, 359 (2). pp. 354-365. ISSN 1521-0103

Access from the University of Nottingham repository:
http://eprints.nottingham.ac.uk/38627/1/C3C5CFBE-8736-483A-A5AC-5D1FBCE94C12.pdf

Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior [S]

Kwok H. C. Choy, David M. Shackleford, Daniel T. Malone, Shailesh N. Mistry,[1]
Rahul T. Patil, Peter J. Scammells, Christopher J. Langmead, Christos Pantelis,
Patrick M. Sexton, Johnathan R. Lane, and Arthur Christopoulos

Drug Discovery Biology (K.H.C.C., D.T.M, C.J.L, P.M.S, J.R.L, A.C.), Centre for Drug Candidate Optimization (D.M.S., R.T.P.), and Medicinal Chemistry (S.N.M, P.J.S), Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia; and Melbourne Neuropsychiatry Centre, Department of Psychiatry and Centre for Neural Engineering, University of Melbourne, Melbourne, Australia (C.P.)

Received June 7, 2016; accepted September 13, 2016

ABSTRACT

Current antipsychotics are effective in treating the positive symptoms associated with schizophrenia, but they remain suboptimal in targeting cognitive dysfunction. Recent studies have suggested that positive allosteric modulation of the M1 muscarinic acetylcholine receptor (mAChR) may provide a novel means of improving cognition. However, very little is known about the potential of combination therapies in extending coverage across schizophrenic symptom domains. This study investigated the effect of the M1 mAChR positive allosteric modulator BQCA [1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid], alone or in combination with haloperidol (a first-generation antipsychotic), clozapine (a second-generation atypical antipsychotic), or aripiprazole (a third-generation atypical antipsychotic), in reversing deficits in sensorimotor gating and spatial memory induced by the N-methyl-D-aspartate receptor antagonist, MK-801 [(5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine]. Sensorimotor gating and spatial memory induction are two models that represent aspects of schizophrenia modeled in rodents. In prepulse inhibition (an operational measure of sensorimotor gating), BQCA alone had minimal effects but exhibited different levels of efficacy in reversing MK-801–induced prepulse inhibition disruptions when combined with a subeffective dose of each of the three (currently prescribed) antipsychotics. Furthermore, the combined effect of BQCA and clozapine was absent in M1$^{-/-}$ mice. Interestingly, although BQCA alone had no effect in reversing MK-801–induced memory impairments in a Y-maze spatial test, we observed a reversal upon the combination of BQCA with atypical antipsychotics, but not with haloperidol. These findings provide proof of concept that a judicious combination of existing antipsychotics with a selective M1 mAChR positive allosteric modulator can extend antipsychotic efficacy in glutamatergic deficit models of behavior.

Introduction

Schizophrenia affects approximately 1% of the population and is characterized by positive, negative, and cognitive symptoms (Pantelis et al., 1997, 1999, 2001; Grube et al., 1998; Harvey et al., 1998; Heinrichs and Zakzanis, 1998; Kandel, 2000; Bora et al., 2009). Current antipsychotics are generally successful in treating the positive symptoms (e.g.,

hallucinations and delusions) but remain largely ineffective in relieving negative and cognitive symptoms and also possess side effects (Speller et al., 1997; Pantelis and Lambert, 2003; Lieberman et al., 2005; Keefe et al., 2007; Gao et al., 2008; Nasrallah, 2008; Sakurai et al., 2013). Hence, there is an unmet need for newer approaches that could target additional symptom domains and produce fewer side effects.

Existing antipsychotics treat positive schizophrenic symptoms by targeting the dopamine system, particularly the D2 receptor (Conn et al., 2008; Miyamoto et al., 2012). The broader, poorly treated, negative and cognitive domains involve additional pharmacological targets. Glutamatergic neurotransmission, in particular that mediated by the N-methyl-D-aspartate receptor (NMDAR), is potentially one such target (Rujescu et al., 2006; Javitt, 2007; Stone et al., 2007; Gordon, 2010). NMDAR antagonists, such as phencyclidine, produce psychotic-like symptoms in humans (Javitt and

ABBREVIATIONS: ACh, acetylcholine; ANOVA, analysis of variance; BQCA, 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; CHO, Chinese hamster ovary; DMSO, dimethylsulfoxide; mAChR, muscarinic acetylcholine receptor; MK-801, (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine; NMDAR, N-methyl-D-aspartate receptor; [3H]NMS, N-[3H] methylscopolamine; PAM, positive allosteric modulator; PPI, prepulse inhibition.

Zukin, 1991; Murray, 2002; Moghaddam and Javitt, 2012). Subanesthetic doses of MK-801 [(5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine], a more potent NMDAR antagonist, also induce animal behaviors that resemble aspects of schizophrenia, such as deficits of gating mechanisms and spatial memory (Bubeníková et al., 2005; Long et al., 2006; Bradford et al., 2010; van der Staay et al., 2011; Bubser et al., 2014). Accordingly, the ability of novel compounds to reduce MK-801–induced behaviors is commonly used as part of a battery of tests that assess preclinical utility of investigational molecules as potential antipsychotics (Enomoto et al., 2008; Bubser et al., 2014; Park et al., 2014).

Muscarinic acetylcholine receptors (mAChRs), in particular central M₁ and M₄ mAChRs, are implicated in learning and memory and have been pursued as therapeutic targets for cognitive dysfunction, including in schizophrenia (Langmead et al., 2008; Lieberman et al., 2008). Furthermore, cholinergic and dopaminergic networks can interact with one another (Lester et al., 2010). For example, stimulation of mAChRs in the ventral tegmental area increases dopamine release in the striatum and frontal cortex (Gronier et al., 2000), and knockout of M₁ mAChRs increases striatal dopamine levels (Gerber et al., 2001). Importantly, the cholinergic system also interacts with glutamatergic transmission; M₁ mAChRs modulate NMDAR current in hippocampal neurons (Jones et al., 2008). Of note, xanomeline, an M₁ and M₄ mAChR-preferring agonist, improved psychotic symptoms in patients with Alzheimer disease and cognitive function in people with schizophrenia (Bodick et al., 1997; Shekhar et al., 2008). However, further clinical development of xanomeline was precluded due to unacceptable side effects, predominantly reflecting off-target activity via the highly conserved orthosteric site at other mAChR subtypes (Bodick et al., 1997; Wood et al., 1999; Bymaster et al., 2002). Encouragingly, mAChRs possess spatially distinct allosteric sites that offer alternative strategies for greater selectivity (Christopoulos, 2002; Bridges et al., 2010; Bolbecker and Shekhar, 2012; Conn et al., 2014; Kruse et al., 2014; Thal et al., 2016). BQCA [1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid], a highly selective M₁ mAChR positive allosteric modulator (PAM) with no reported off-target activities, reversed scopolamine-disrupted memory, rescued memory deficits in a mouse model of Alzheimer disease, and also had procognitive effects on baseline memory performance (Ma et al., 2009; Shirey et al., 2009; Chambon et al., 2011, 2012; Galloway et al., 2014). The effects may be due to activation of neurons in the prefrontal cortex and hippocampus, as these regions express high levels of M₁ mAChRs (Porter et al., 2002; Ma et al., 2009).

The superior efficacy of existing atypical antipsychotics may be related to their complex polypharmacology (Miyamoto et al., 2005). However, less is known about the potential of combination therapies for improved treatment of negative and cognitive schizophrenic domains. Most atypical antipsychotics have limited affinity for the M₁ mAChR; however, a few (e.g., clozapine and olanzapine) are antagonists at the M₁ mAChR, an action linked to acute memory impairment (Bymaster et al., 1999; Didriksen et al., 2006; Mutlu et al., 2011; Miyamoto et al., 2012). Hence, coadministration of a compound that could specifically activate or potentiate the M₁ mAChR together with select current antipsychotics may offer additional therapeutic value in extending antipsychotic efficacy. This study thus aimed to investigate the effects of a combination of BQCA with selected typical and atypical antipsychotics on MK-801–induced behaviors in mice, specifically prepulse inhibition (PPI) disruption and impaired memory in the Y-maze spatial test.

Materials and Methods

Materials. Chinese hamster ovary (CHO) FlpIn cells and Dulbecco's modified Eagle's medium were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum was purchased from ThermoTrace (Melbourne, Australia). Hygromycin-B was purchased from Roche (Mannheim, Germany). N-[³H] methylscopolamine ([³H]NMS; specific activity, 85 Ci/mmol) and Ultima gold scintillation liquid were purchased from PerkinElmer Life Sciences (Boston, MA). BQCA, clozapine, and aripiprazole were synthesized in-house, and all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). FlpIn CHO cells stably expressing the human M₁ mAChR were generated and maintained as described previously (Abdul-Ridha et al., 2014).

In Vitro Competition Binding Assays. FlpIn CHO cells expressing the human M₁ mAChR were plated at 25,000 cells per well in 96-well Isoplates (PerkinElmer Life Sciences). The next day, cells were incubated in a final volume of 100 μl HEPES buffer (10 mM HEPES, 145 mM NaCl, 1 mM MgSO₄·7H₂O, 10 mM glucose, 5 mM KCl, 2 mM CaCl₂, and 1.5 mM NaHCO₃, pH 7.4) containing increasing concentrations of a competing cold ligand carbachol (in the absence or presence of 10 μM BQCA) in the presence of 0.1 nM [³H]NMS for 4 hours at 4°C (to avoid potential confounding effects of competing agonist ligands on receptor internalization while ensuring reactions reached equilibrium). Nonspecific binding was defined in the presence of 100 μM atropine. For all experiments, termination of the assay was performed by rapid removal of the radioligand followed by two 100-μl washes with ice-cold 0.9% NaCl buffer. Radioactivity was determined by addition of 100 μl Microscint scintillation liquid (PerkinElmer Life Sciences) to each well and counting in a MicroBeta plate reader (PerkinElmer Life Sciences).

Animals and Drugs. The experiments were performed using 2- to 4-month-old male C57Bl/6J, M₁ mAChR homozygous knockout (M₁⁻/⁻), and wild-type (M₁⁺/⁺) mice in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Behavioral testing procedures were approved by the Animal Ethics Committee of the Monash Institute of Pharmaceutical Sciences. The M₁⁻/⁻ mice, which were backcrossed to C57Bl/6N for more than 11 generations, and both M₁⁺/⁺ and M₁⁻/⁻ mice shared the same C57Bl/6N background (Bymaster et al., 2003; Thomsen et al., 2010). They were bred and genotyped at the Monash Institute of Pharmaceutical Sciences (Parkville, Australia). Mice were housed on a reversed light/dark cycle (lights on 7 PM) with ad libitum access to food and water. As outlined in the *Results* and in Table 1, two different routes of administration were used: C57Bl/6J mice received BQCA via subcutaneous injection, as per a previous study in this mouse strain from our laboratory when investigating another class of mAChR PAM (Suratman et al., 2011), and were tested in both PPI and Y-maze behavioral tests. However, prior studies have shown that M₁⁺/⁺ and M₁⁻/⁻ mice on a C57Bl/6N substrain background can exhibit a different PPI profile (Matsuo et al., 2010) compared with C57Bl/6J mice. Given the limited number of animals available for these latter studies and our desire to maximize interanimal consistency, we performed new pharmacokinetic studies that revealed that intraperitoneal injection of BQCA (in a solubilized formulation) resulted in higher exposure in this instance (see *Results*). BQCA (1–20 mg/kg) was suspended in a combination of 50% Pharmasolve (Ashland Inc., Bridgewater, NJ) and 1.1% Tween 20 (Sigma-Aldrich, Castle Hill, Australia) in injection water (PLP, Glendenning, Australia) for subcutaneous injection (Suratman et al., 2011), or dissolved in 15% dimethylsulfoxide (DMSO) (Sigma-Aldrich), 2% Tween 20, and 22 mM Tris buffer (pH 8.9) for intraperitoneal injection. Together with BQCA administration (subcutaneously or intraperitoneally), animals received a single intraperitoneal dose of 0.03–0.25 mg/kg haloperidol

TABLE 1
Experimental groups and reports of ANOVA analysis

Behavioral Test	Mouse Strain	No. of Mice	Drugs (Route)	Main Effects and Interactions after ANOVA Analysis		
				Cohort	F Value	P Value
PPI	C57Bl/6J	Vehicle and MK-801 controls, 15–17; others, 9–10	BQCA (s.c.) + antipsychotics (i.p.)	MK-801 overall	$F_{(1,\ 343)} = 315.3$	<0.001
				BQCA alone	None	
				BQCA + haloperidol		
				BQCA effect	$F_{(4,\ 174)} = 4.3$	0.002
				Haloperidol effect	$F_{(1,\ 174)} = 45.0$	<0.001
				BQCA × haloperidol interaction	$F_{(4,\ 174)} = 3.3$	0.013
				BQCA + clozapine		
				BQCA effect	$F_{(4,\ 165)} = 2.7$	0.032
				Clozapine effect	$F_{(1,\ 165)} = 31.6$	<0.001
				BQCA + aripiprazole		
				BQCA effect	$F_{(4,\ 160)} = 2.7$	0.031
				Aripiprazole effect	$F_{(1,\ 160)} = 24.6$	<0.001
				Prepulses × BQCA × Aripiprazole × MK-801 interaction	$F_{(4,\ 320)} = 4.5$	0.002
Y-maze	C57Bl/6J	10–13	BQCA (s.c.) + antipsychotics (i.p.)	BQCA alone		
				Arm effect	$F_{(1,\ 59)} = 17.2$	<0.001
				Arm × MK-801 effect	$F_{(1,\ 59)} = 9.7$	0.003
				BQCA + haloperidol		
				Arm effect	$F_{(1,\ 124)} = 8.4$	0.005
				Arm × MK-801 effect	$F_{(1,\ 124)} = 6.4$	0.012
				BQCA + clozapine		
				Arm effect	$F_{(1,\ 123)} = 13.4$	<0.001
				Arm × MK-801 effect	$F_{(1,\ 123)} = 5.1$	0.026
				Arm × BQCA effect	$F_{(2,\ 123)} = 3.5$	0.034
				BQCA + aripiprazole		
				Arm effect	$F_{(1,\ 132)} = 18.0$	<0.001
				Arm × MK-801 effect	$F_{(1,\ 132)} = 8.6$	0.004
PPI	$M_1^{+/+}$ mice (C57Bl/6 Ntac background)	Vehicle and MK-801 controls, 15–16; others, 8–9	BQCA (i.p.) + clozapine (i.p.)	$M_1^{+/+}$ mice		
	$M_1^{-/-}$ mice (C57Bl/6 Ntac background)	Vehicle and MK-801 controls, 13–15; others, 8		MK-801 effect	$F_{(1,\ 67)} = 29.0$	<0.001
				BQCA effect	$F_{(2,\ 67)} = 3.2$	0.046
				Clozapine effect	$F_{(1,\ 67)} = 8.3$	0.005
				$M_1^{-/-}$ mice		
				MK-801 effect	$F_{(1,\ 61)} = 26.2$	<0.001

(Tocris, Bristol, UK) (dissolved in 1% DMSO saline), 0.5–2 mg/kg clozapine, or 2.5 mg/kg aripiprazole (dissolved in 2% Tween 20 saline). Twenty-five minutes later, mice received an intraperitoneal injection of 0.15 or 0.3 mg/kg MK-801 (Sigma-Aldrich) dissolved in 0.1% ascorbic acid saline, and mice were then subjected to PPI or a Y-maze training session (Y_{train}) 20 minutes afterward (see *Results* and figures for timelines). The doses of antipsychotics were specifically chosen to be subeffective in the model under test, based on previous studies (haloperidol; Bast et al., 2000), or pilot studies conducted in-house (clozapine and aripiprazole). Our pilot study showed that 4 mg/kg clozapine, or 20 mg/kg aripiprazole, reversed PPI disruption induced by 0.3 mg/kg MK-801. Haloperidol, at any doses below those that cause catalepsy (i.e., <0.5 mg/kg, above which catalepsy is observed), was ineffective at reversing the MK-801 effect. In addition, all antipsychotic doses used were either lower than (aripiprazole and clozapine) or within (haloperidol) the clinically comparable range with regard to their likely dopamine D_2 receptor occupancies in humans (Kapur et al., 2003; Natesan et al., 2011).

Assessment of BQCA Exposure. BQCA exposure was assessed in three separate pharmacokinetic studies (see *Results*). Separate groups of C57Bl/6J, $M_1^{+/+}$, and $M_1^{-/-}$ behavioral naïve mice were administered BQCA (subcutaneously or intraperitoneally), with antipsychotics (2 mg/kg clozapine, 0.25 mg/kg haloperidol, or 2.5 mg/kg aripiprazole), or vehicle and were euthanized at time points relevant

to the collection of behavioral data (i.e., 45, 90, or 180 minutes postdose). Concentrations of BQCA or antipsychotics, in plasma and/or brain homogenate, were determined via ultra-performance liquid chromatography/mass spectrometry. The concentration of BQCA in the brain parenchyma (C_{brain}) was calculated on the basis of the measured concentration in the brain homogenate ($C_{brain\ homogenate}$), after correcting for the contribution of compound contained within the vascular space of brain samples as follows:

$C_{brain} = C_{brain\ homogenate} - C_{brain\ vasculature}$, where $C_{brain\ vasculature}$ is $C_{plasma} \times V_p$.

C_{brain}, $C_{brain\ homogenate}$, and $C_{brain\ vasculature}$ are the concentrations of compound in the brain parenchyma, brain homogenate, and brain vasculature, respectively (in nanograms per gram). C_{plasma} is the concentration of compound in plasma (in nanograms per milliliter). V_p is the brain plasma volume (0.017 μl/g for C57Bl6 mice; Nicolazzo et al., 2010).

The unbound concentration of BQCA ($C_{unbound}$) in the brain parenchyma was then calculated as $C_{total} \times f_u$, using published fraction free concentration (f_u) values for BQCA (i.e., $f_{u,brain} = 0.126$; Gould et al., 2015). Otherwise, the total concentration of antipsychotics (C_{total}) is presented. The data are expressed in nanomolar units assuming a brain density of 1 g/ml.

PPI Test. PPI was performed in a sound-attenuated room using SR-LAB startle chambers (San Diego Instruments, San Diego, CA). Mice subjected to PPI testing received BQCA (1–20 mg/kg) with or without antipsychotics, and then MK-801 (0.3 mg/kg) or its vehicle. Each PPI session lasted for 1 hour and consisted of three startle pulses (p100, p110, and p120) and was also preceded with 6-, 12-, and 18-db prepulses above a 65-db background for each pulse (referred to as pp6, pp12, and pp18, respectively), to provide a more comprehensive characterization of PPI (Yee et al., 2005). In the first PPI study conducted in C57Bl/6J mice, all treatment groups were pseudorandomized on each testing day, with at least one vehicle– and MK-801–only treated mouse included as a control per PPI testing day. There were 15–17 mice for the vehicle-only or MK-801–only treatment groups, and there were 9–10 mice for all other treatment groups. The second PPI study was conducted in both $M_1^{+/+}$ and $M_1^{-/-}$ mice using the same PPI protocol, with 13–16 mice for the vehicle and MK-801 controls and 8–9 mice for the other treatment groups. In these PPI studies, the drug effect on the overall PPI measured at the three startle pulses (i.e., p100, p110, and p120) was found to be similar; hence, only PPI data analysis obtained from p120 is reported. To simplify data presentation, the average PPI (%) is presented in the figures, and PPI (%) measured at each prepulse (pp6, pp12, and pp18) is detailed in Table 2. There was no change to the startle response in mice, except for those treated with the highest dose (20 mg/kg) of BQCA (in the presence of MK-801) (Supplemental Fig. 1). The average PPI data of p100 and p110 are presented in Supplemental Fig. 2.

Y-Maze Test. Mice received BQCA, clozapine, haloperidol, aripiprazole, or a combination of BQCA and an antipsychotic before MK-801 (0.15 mg/kg) injection. Since a lower dose of MK-801 (compared with 0.3 mg/kg used in PPI) was sufficient to disrupt spatial memory formation in the Y-maze, the dose range of BQCA chosen was also reduced to 5–10 mg/kg. The ranges of the antipsychotics were also reduced relative to those used in the PPI studies: haloperidol, 0.03 to 0.06 mg/kg; clozapine, 0.5 to 1 mg/kg; and aripiprazole, 0.125 to 0.25 mg/kg. Higher doses of aripiprazole (i.e., >0.25 mg/kg) were excluded, because mice had significantly lower locomotor activity in both training and testing sessions. Y-maze experiments were conducted in a manner similar to those previously described with 10–13 mice per treatment group (Dellu et al., 1992; Choy et al., 2008; Shipton et al., 2014). In brief, mice were allowed to explore two arms, with the novel arm closed, in a training session (Y_{train}) that lasted for 10 minutes. Two hours later, the same mice were allowed to explore all three arms for 5 minutes in the testing session (Y_{test}). Behavior was recorded and analyzed with video tracking software (Viewer III; Biobserve GmbH, Bonn, Germany), and the time spent in each arm, during the testing session, was used as a measure of the exploratory preferences of mice. A significant difference between novel and familiar arms was considered as a measure of baseline memory function. In a preliminary study, prior to the full Y-maze test, MK-801 disrupted memory function when it was administered before the training session rather than after (data not shown). This finding is consistent with a previous study in which MK-801 disrupted memory in a novel objection recognition test in mice (Nilsson et al., 2007), suggesting that NMDARs blocked by MK-801 disrupt memory acquisition during the training phase. The Y-maze data of mice treated with the same vehicle used to administer MK-801 (i.e., 0.1% ascorbic acid in saline) and a combination of BQCA and antipsychotics are also reported in Supplemental Fig. 3.

Data Analysis. For the in vitro studies, competition binding parameters were determined via nonlinear regression as described previously (Canals et al., 2012). All affinity values were estimated as logarithms, and statistical comparisons between values were performed by t tests using GraphPad Prism software (version 6.0; GraphPad Software Inc., La Jolla, CA). Behavioral data were analyzed using IBM SPSS (version 22.0; IBM, Armonk, NY). PPI (%) was analyzed with analysis of variance (ANOVA) with repeated measures of prepulses (pp6, pp12, and pp18), with drug treatments as main factors. Tukey's post hoc test was then used to determine the level of significance at each prepulse and average values of PPI (%) among groups when there was a main drug effect or an interaction. For Y-maze data, the time spent in novel and familiar arms is presented (in seconds). If the overall main arm effect was significant in each cohort, pairwise ANOVA comparisons were performed between the

TABLE 2

PPI measured with prepulses at 6, 12, and 18 db above the background in C57Bl/6J mice, which received BQCA via the subcutaneous route

Data are presented as means ± S.E.M.

Drug	PPI		
	pp6	pp12	pp18
		%	
Vehicle control	23.6 ± 3.4	36.2 ± 3.0	50.3 ± 2.4
MK-801	−3.0 ± 3.2*	15.7 ± 3.6*	17.4 ± 2.5*
+ 1 mg/kg BQCA	1.1 ± 5.1	12.1 ± 4.7	17.5 ± 6.8
+ 3 mg/kg BQCA	0.8 ± 6.2	6.9 ± 5.0	4.6 ± 5.0
+ 10 mg/kg BQCA	1.4 ± 5.7	11.1 ± 6.0	21.4 ± 6.1
+ 20 mg/kg BQCA	−8.0 ± 4.9	6.2 ± 3.9	17.9 ± 2.5
MK-801 + 0.25 mg/kg haloperidol	4.4 ± 2.0	22.1 ± 3.5	37.1 ± 4.4
+ 1 mg/kg BQCA	6.2 ± 3.6	18.8 ± 3.1	35.6 ± 2.9
+ 3 mg/kg BQCA	7.7 ± 2.7	23.9 ± 4.2	37.8 ± 5.5
+ 10 mg/kg BQCA	10.9 ± 2.9	23.7 ± 3.5	36.9 ± 4.4
+ 20 mg/kg BQCA	12.9 ± 2.0	34.4 ± 4.4	57.8 ± 4.7**
MK-801 + 2 mg/kg clozapine	9.4 ± 3.7	25.7 ± 4.6	37.9 ± 6.2
+ 1 mg/kg BQCA	8.4 ± 2.6	16.7 ± 2.8	36.3 ± 4.2
+ 3 mg/kg BQCA	3.7 ± 6.0	12.5 ± 6.8	27.5 ± 4.9
+ 10 mg/kg BQCA	0.2 ± 3.8	22.4 ± 4.4	38.0 ± 4.4***
+ 20 mg/kg BQCA	14.0 ± 8.0	32.6 ± 4.7	56.4 ± 4.9**
MK-801 + 2.5 mg/kg aripiprazole	8.2 ± 3.2	20.7 ± 3.5	27.7 ± 4.3
+ 1 mg/kg BQCA	0.1 ± 3.8	11.9 ± 5.8	22.7 ± 6.9
+ 3 mg/kg BQCA	−3.6 ± 5.2	14.4 ± 4.2	30.3 ± 3.9
+ 10 mg/kg BQCA	10.0 ± 2.9	17.9 ± 3.9	32.0 ± 4.9
+ 20 mg/kg BQCA	3.9 ± 4.5	26.2 ± 5.2	47.0 ± 3.1**

*$P < 0.05$ (versus vehicle control − MK-801 effect); **$P < 0.001$ (versus MK-801 control at the same prepulse); ***$P < 0.05$ (versus MK-801 control at the same prepulse).

novel and familiar arms in each group. Both PPI and Y-maze data analysis were divided into BQCA alone, BQCA plus haloperidol, BQCA plus clozapine, and BQCA plus aripiprazole cohorts and included their vehicle control in the ANOVA analysis. The drug effects and interactions after the ANOVA analysis are reported in Table 1, and post hoc tests are reported in the *Results* and/or indicated in the figures. Data are presented as means ± S.E.M. A value of $P < 0.05$ was considered statistically significant.

Results

BQCA, But Not Typical or Atypical Antipsychotics, Acts as a PAM of Acetylcholine at the M_1 mAChR. BQCA is a highly selective PAM of acetylcholine (ACh) binding and function at the M_1 mAChR (Ma et al., 2009; Canals et al., 2012). Therefore, any effect of BQCA in vivo is most likely mediated by its interaction with the M_1 mAChR. Nonetheless, to ensure that there is no specific on-target allosteric interaction between BQCA and the selected antipsychotics, we performed competition-binding experiments using the radioligand [^{3}H]NMS on CHO FlpIn cells stably expressing the human M_1 mAChR. As expected, clozapine displayed submicromolar affinity for the M_1 mAChR ($K_i = 0.3\ \mu$M; Fig. 1A). In contrast, neither haloperidol nor aripiprazole was able to fully inhibit [^{3}H]NMS binding, even at a concentration of 100 μM. Although 10 μM BQCA caused a significant (60-fold) increase in ACh affinity, in agreement with our previous findings (Abdul-Ridha et al., 2014), BQCA had no effect on the affinity of clozapine (Fig. 1B); BQCA also had no effect on haloperidol and aripiprazole (data not shown). Therefore, BQCA does not modulate the binding of the selected antipsychotics at the M_1 mAChR.

Brain Exposure of BQCA. The apparent brain/plasma ratio from our in vivo exposure study (data not shown) was consistent with that observed previously (Ma et al., 2009; Shirey et al., 2009; Gould et al., 2015). Also, there was a clear dose-dependent increase in brain exposure in all cohorts of mice with BQCA administered via subcutaneous or intraperitoneal injection (Supplemental Fig. 4A). Of note, all C57Bl/6J mice used in the behavioral studies reported in the main text received BQCA via the subcutaneous route. In the last PPI study using $M_1^{+/+}$ and $M_1^{-/-}$ mice (see below), the animals received BQCA dissolved in DMSO-based vehicle via intraperitoneal injection, as in vivo exposure data indicated that this method of administration resulted in higher overall exposure of BQCA in this substrain (Supplemental Fig. 4B). Importantly, as shown in Supplemental Fig. 4C, in no instance was the brain exposure of either BQCA or any of the antipsychotics increased when mice were dosed with both classes of compound. Therefore, any observed behavioral effects of the combination are not a result of increased exposure at their respective sites of action.

BQCA Alone Does Not Rescue MK-801–Induced Disruptions in PPI. The main effect of MK-801 in all cohorts of mice (Table 1) confirmed a significant PPI disruption in MK-801–treated mice (Figs. 2 and 3). However, there was an absence of a BQCA effect in the BQCA-alone cohort, suggesting that BQCA alone did not have any substantial rescuing effects on PPI disruption induced by MK-801 (Fig. 2B).

Combination of Subeffective Doses of BQCA with Typical or Atypical Antipsychotics Produces Significant Reversals in MK-801–Induced Disruptions in PPI. As indicated in the *Materials and Methods*, the dose of haloperidol (0.25 mg/kg) was specifically chosen from prior studies to represent a subeffective dose level in the PPI

Fig. 1. BQCA does not allosterically modulate antipsychotics at the M_1 mAChR. (A) Antipsychotic affinity was measured at the human M_1 mAChR stably expressed in CHO cells using competition binding experiments with the antagonist [^{3}H]NMS. Clozapine (pK_B = 6.46 ± 0.10) displayed significant affinity for the M_1 mAChR. In contrast, even at a maximal concentration of 100 μM, haloperidol and aripiprazole were unable to completely displace [^{3}H]NMS. (B) Competition binding studies between ACh or clozapine with [^{3}H]NMS were performed in the absence (open bars) and presence (filled bars) of 10 μM BQCA. BQCA (10 μM) caused a significant 60-fold increase in ACh affinity ($P < 0.001$, two-tailed t test) but had no significant effect on the affinity of clozapine.

studies. In the BQCA plus haloperidol cohort, there was a significant BQCA × haloperidol effect (Table 1) as an indication of a synergistic effect between the two compounds. Post hoc analysis (Table 2) showed that MK-801–induced disruption in PPI was not fully reversed by either haloperidol alone or a combination of haloperidol with 1–10 mg/kg BQCA. However, a complete reversal of MK-801–induced PPI disruption was observed when the subeffective dose of haloperidol was combined with 20 mg/kg BQCA (Fig. 3A). Similarly, clozapine (2 mg/kg) alone and in combination with 1–10 mg/kg BQCA failed to fully reverse MK-801–induced PPI disruption. However, a significant reversal was observed with the combination of clozapine and BQCA (20 mg/kg) (Fig. 3B), although there was an absence of BQCA by clozapine interaction in the ANOVA, indicating that both BQCA and clozapine were likely behaving additively rather than synergistically. Comparable trends were also observed in the aripiprazole plus BQCA cohort, but only at the highest prepulse tested (i.e., pp18) (Fig. 3C; Table 2). In this instance, the significant prepulse by BQCA by aripiprazole interaction (Table 1) indicated the presence of a synergistic effect of PPI measured at pp18. Taken together, these results reveal that

Fig. 2. BQCA alone has minimal effects on MK-801–induced disruptions in PPI. (A) A timeline of drug treatment and PPI testing is presented. MK-801 (0.3 mg/kg, i.p.) was administered 25 minutes after BQCA and antipsychotics, and mice were subjected to PPI testing 20 minutes after MK-801 treatment. (B) MK-801 (0.3 mg/kg, i.p.) induced significant PPI disruption in C57Bl/6J mice. BQCA (0–20 mg/kg, s.c.) did not reverse the MK-801–disrupted PPI. ^P < 0.05 (for significant MK-801– induced disruption). Data are presented as means ± S.E.M. (vehicle– and MK-801–only controls, n = 15–17, which were reused in each cohort set, in this figure and in Fig. 3; and other treatment groups, n = 9–10).

BQCA enhanced subeffective doses of commonly used antipsychotics to produce a rescue of PPI deficits in MK-801–treated mice.

BQCA Enhanced the Rescuing Effect of Clozapine or Aripiprazole, But Not That of Haloperidol, in the Y-Maze Test. To explore memory performance, the duration spent (in seconds) in novel and familiar arms for each treatment group was analyzed (Table 1). There was a main arm effect and a significant arm × MK-801 interaction, indicating disruption of short-term memory in the Y-maze test by MK-801 (Table 1). Further analysis revealed differences between the novel and familiar arms in vehicle-treated mice (P = 0.002; Fig. 4B). In MK-801–treated mice, pretreatment with 10 mg/kg BQCA and 1 mg/kg clozapine (P = 0.007; Fig. 5B), or 5 mg/kg BQCA and 0.125 mg/kg aripiprazole (P = 0.026; Fig. 5C), also showed novel versus familiar arm differences, which is indicative of normal memory function as seen in vehicle control mice (Fig. 5). There were no differences in the other treatment groups, including BQCA alone or in combination with haloperidol (Fig. 5A). These results demonstrate a synergistic effect between BQCA and the atypical antipsychotics, clozapine or aripiprazole, on memory function, which was not seen with BQCA on its own or in combination with haloperidol, in this acute memory disruption model.

M$_1$ mAChR Is Required for the Combined Effect of BQCA and Clozapine in Reversing PPI Deficits. To confirm the requirement of the M$_1$ mAChR for the observed combined effect, we repeated selected key BQCA and clozapine interaction studies in mice lacking the M$_1$ mAChR; this also necessitated testing in different background mouse strains. The combined effect between BQCA and clozapine

seen in reversing MK-801–induced PPI deficits was reproducible in C57Bl/6J mice using this administration method (Supplemental Fig. 5). Moreover, consistent with previous findings (Matsuo et al., 2010), we noted that both M$_1^{+/+}$ and M$_1^{-/-}$ mice on a C57Bl/6N background exhibited a higher PPI compared with the C57Bl/6J mice used in the preceding studies. PPI disruption was induced to a similar extent by 0.3 mg/kg MK-801 in both M$_1^{+/+}$ and M$_1^{-/-}$ mice. A partial,


Fig. 3. Combination of subeffective doses of BQCA and haloperidol or clozapine can reverse MK-801–induced disruption in average PPI. (A and B) Both haloperidol (0.25 mg/kg) and clozapine (2 mg/kg) did not reverse MK-801–induced PPI disruption; however, the combination with BQCA (20 mg/kg, s.c.) resulted in significant reversal of PPI disruption in C57Bl/6J mice. (C) The combination of BQCA (20 mg/kg, s.c.) and aripiprazole did not produce a reversal in average PPI, except PPI measured at pp18 (Table 2). *P < 0.05 (for difference with MK-801 post hoc comparisons); **P < 0.001 (for difference with MK-801 post hoc comparisons); ^P < 0.05 (for significant MK-801–induced disruption). Data are presented as means ± S.E.M. (vehicle– and MK-801–only controls, n = 15–17, which were reused in each cohort set, in this figure and in Fig. 2; and other treatment groups, n = 9–10).

but statistically nonsignificant, reversal of the PPI deficit was observed after dosing clozapine alone, consistent with the observation in C57Bl/6J mice (Fig. 6). A qualitatively similar partial reversal was observed after $M_1^{+/+}$ mice received BQCA alone at 20 mg/kg, a trend that was not observed in C57Bl6J mice. This reversal failed to achieve statistical significance and was not observed in subsequent studies with further cohorts of $M_1^{+/+}$ mice. The most important finding, however, was that MK-801–disrupted PPI was rescued by the combination of BQCA (20 mg/kg) and clozapine (3 mg/kg) in the $M_1^{+/+}$ mice, and there was a complete absence of such rescue in the $M1^{-/-}$ mice receiving the same treatment (Fig. 6; Table 3). These results demonstrate the selectivity of BQCA in vivo and also confirm that the M_1 mAChR is required in order to observe efficacy enhancement of clozapine actions.

Discussion

This study provides proof of concept that the combination of an M_1 mAChR PAM with different antipsychotic drugs can yield synergistic (or additive) efficacy in two animal behavioral models that are considered to reflect aspects of schizophrenia. These effects are not mediated by on-target allosteric interactions at the M_1 mAChR between BQCA and the antipsychotics, but activation of the receptor is necessary because the interaction between BQCA and clozapine in reversing MK-801–induced PPI disruption is lost in $M_1^{-/-}$ mice. If these findings can be generalized to other aspects or models of schizophrenia, then this may provide impetus for future consideration of the use of M_1 mAChR PAMs as potential add-on therapies to selected existing drug regimens.

Haloperidol is a first-generation antipsychotic agent, representative of the requirement for potent dopamine D_2 receptor


Fig. 4. MK-801 induces spatial memory deficits in C57Bl/6J mice in the Y-maze test. (A) A timeline of drug treatment and Y-maze testing is presented. BQCA and antipsychotics were given 25 minutes prior to MK-801 (0.15 mg/kg) administration, and the mice were then subjected to a Y-maze training session 20 minutes after MK-801 treatment. The retention period was 2 hours (between training [Y_{train}] and testing [Y_{test}] sessions). The duration spent (in seconds) in the novel and familiar arms was used as the measure of memory function. (B) Analysis showed no rescue of memory deficits induced by MK-801 (0.15 mg/kg) for mice pretreated with BQCA alone. *$P < 0.05$ (for difference between the novel and familiar arms as an indication of normal memory function). Data are presented as means ± S.E.M. (n = 10–13 mice per group). N, novel.


Fig. 5. The combination of BQCA with clozapine or aripiprazole, but not with haloperidol, improves MK-801–induced spatial memory in C57Bl/6J mice in the Y-maze test. (A) Mice pretreated with BQCA combined with haloperidol showed no rescue of MK-801–induced memory disruption. (B and C) In contrast, mice treated with combinations of BQCA (10 mg/kg, s.c.) and clozapine (1 mg/kg), or BQCA (5 mg/kg, s.c.) and aripiprazole (0.125 mg/kg), showed rescue of the MK-801 (0.15 mg/kg) memory disruptive effect. *$P < 0.05$ (for difference between the novel and familiar arms as an indication of normal memory function). Data are presented as means ± S.E.M. (n = 10–13 mice per group). N, novel.

antagonism in treating positive schizophrenic symptoms (Mansbach et al., 1988; Conn et al., 2008; Miyamoto et al., 2012). Clozapine was chosen as an atypical second-generation antipsychotic with a broad polypharmacology profile (Miyamoto et al., 2005; Nasrallah, 2008), whereas aripiprazole was selected as a third-generation agent that acts on D_2 receptors as a partial agonist with a lower propensity toward adverse metabolic side effects (Nasrallah, 2008; Cui et al., 2010). None of these drugs, however, are effective at treating cognitive deficits associated with schizophrenia (Lieberman et al., 2005; Lublin et al., 2005). However, therapeutic targeting has not been limited to D_2 receptors (Conn et al., 2008; Owen et al., 2016). For example, agents targeting mAChRs that are highly expressed in affected

Fig. 6. The enhancement of efficacy of clozapine by BQCA in reversing PPI deficits is absent in M_1 mAChR knockout mice. MK-801 (0.3 mg/kg) induced PPI disruption in both $M_1^{+/+}$ mice (top) and $M_1^{-/-}$ mice (bottom). Despite differences in the PPI profile between C57Bl/6J and $M_1^{+/+}$ (C57Bl/6N background) mice, an additive effect of BQCA (20 mg/kg, i.p.) and clozapine (3 mg/kg) was still observed in the $M_1^{+/+}$ mice but not in the $M_1^{-/-}$ mice. The synergetic effect was particularly significant at pp6 (Table 3). *$P < 0.05$ (for difference with MK-801 post hoc comparisons); ^$P < 0.05$ (for significant MK-801–induced disruption). Data are presented as means ± S.E.M. ($M_1^{+/+}$ vehicle and MK-801 controls, $n = 15$–16; $M_1^{+/+}$ treatment groups, $n = 8$–9; $M_1^{-/-}$ vehicle and MK-801 controls, $n = 13$–15; and $M_1^{-/-}$ treatment groups, $n = 8$).

regions, such as the prefrontal cortex and hippocampus, have received attention for their potential in rescuing cognitive dysfunction (Bymaster et al., 2002; Shekhar et al., 2008;

Bridges et al., 2010; Barak and Weiner, 2011; Bolbecker and Shekhar, 2012). In this study, we specifically focused on NMDAR antagonism by MK-801 as a means of modeling sensorimotor deficits and short-term memory disruption due to glutamatergic hypofunction (Gilmour et al., 2012), as opposed to pharmacological interventions such as amphetamine that model positive symptom domains but are more limited for studying negative or cognitive domains (Young et al., 2010; Katsnelson, 2014). For behavioral models, the PPI test measures sensorimotor gating in the brain, as it is impaired in patients with schizophrenia, and has been used in animals to identify and understand antipsychotic efficacies of clinically available drugs (Keith et al., 1991; Bakshi et al., 1994; Swerdlow et al., 1994; Swerdlow and Geyer, 1998; Cadenhead et al., 1999; Young et al., 2010; Moore et al., 2013). The Y-maze test is a short-term spatial memory paradigm for assessing hippocampal-dependent memory function (Conrad et al., 1996, 1997; Choy et al., 2008; Shipton et al., 2014), which is highly vulnerable to pathologic factors such as stress (Heckers et al., 1998; Harrison, 2004; Sweatt, 2004; van Erp et al., 2004, 2016; Tanskanen et al., 2005; Vakalopoulos, 2006; Velakoulis et al., 2006; Choy et al., 2008) and is impaired from the earliest stages of schizophrenia (Wood et al., 2002, 2003). Therefore, the Y-maze test has potential to provide preclinical insights into the effects of combining BQCA and antipsychotics on brain regions affected along the pathologic trajectory of schizophrenia (Heckers et al., 1998; Weinberger, 1999; Lipska and Weinberger, 2002; Harrison, 2004; Sweatt, 2004; van Erp et al., 2004; Harrison and Weinberger, 2005; Tanskanen et al., 2005; Velakoulis et al., 2006)

In general, BQCA alone had minimal effects in both behavioral models. With the exception of the highest dose of clozapine (5 mg/kg), which also affected the animal startle response, the doses of haloperidol, clozapine, and aripiprazole used in this study were insufficient to restore normal PPI after MK-801 treatment, consistent with findings from previous studies (Bakshi et al., 1994; Bast et al., 2000; Ishii et al., 2010). However, it should be noted that this subeffective dosing was necessary to reveal the effect of combination with BQCA.

TABLE 3

PPI measured with prepulses at 6, 12, and 18 db above the background in $M_1^{+/+}$ and $M_1^{-/-}$ (C57Bl/6 Ntac background) mice, which received BQCA via the intraperitoneal route

Data are presented as means ± S.E.M.

Group	PPI		
	pp6	pp12	pp18
	%		
$M_1^{+/+}$ mice			
Vehicle control	46.8 ± 3.9	69.0 ± 4.1	76.4 ± 3.6
MK-801	0.9 ± 8.6*	27.8 ± 9.3*	45.1 ± 7.1*
+ 1 mg/kg BQCA	−2.4 ± 6.1	28.1 ± 8.4	35.0 ± 10.7
+ 20 mg/kg BQCA	14.0 ± 6.3	42.2 ± 5.3	63.0 ± 4.9
MK-801 + 3 mg/kg clozapine	10.9 ± 9.6	39.8 ± 9.4	58.3 ± 6.1
+ 1 mg/kg BQCA	19.4 ± 4.5	44.4 ± 4.6	59.5 ± 5.2
+ 20 mg/kg BQCA	34.7 ± 5.0**	54.0 ± 4.8	68.8 ± 2.7
$M_1^{-/-}$ mice			
Vehicle control	35.4 ± 4.0	65.7 ± 2.4	75.5 ± 2.4
MK-801	8.7 ± 4.8*	41.9 ± 4.8*	57.0 ± 2.6*
+ 1 mg/kg BQCA	14.3 ± 5.9	45.2 ± 4.5	59.9 ± 4.6
+ 20 mg/kg BQCA	17.4 ± 4.2	47.3 ± 4.6	59.1 ± 3.2
MK-801 + 3 mg/kg clozapine	16.4 ± 6.0	50.9 ± 5.6	65.8 ± 3.4
+ 1 mg/kg BQCA	16.7 ± 5.7	46.7 ± 4.9	58.0 ± 4.8
+ 20 mg/kg BQCA	23.4 ± 8.3	51.5 ± 4.7	62.7 ± 6.2

*$P < 0.05$ (versus vehicle control − MK-801 effect); **$P < 0.05$ (versus MK-801 control at the same prepulse).

Lowering doses of antipsychotics also brings potential benefits, because the side-effect burden would be lessened if therapeutically effective lower doses were to be administered clinically. The fact that coadministration of the M_1 mAChR PAM with each of the three classes of antipsychotic rescued the disrupted PPI response indicates that sensorimotor gating deficits can be particularly amenable to combination therapy, even in the case of clozapine, which itself has affinity for the M_1 mAChR. Presumably, potentiation of endogenous ACh affinity at this receptor by BQCA, however, would reduce M_1 mAChR occupancy by clozapine (and its metabolites) in preference for the full agonist, ACh. Importantly, we confirmed that the combined effect of BQCA and clozapine was reproducible in the $M_1^{+/+}$ mice but lost in the $M_1^{-/-}$ mice, despite differences in the overall PPI profile between the C57Bl/6 substrains (Matsuo et al., 2010).

In addition to sensorimotor gating deficits, spatial memory dysfunction, which is mostly associated with decline of hippocampal function, has been commonly observed in patients with schizophrenia, even at early onset stages (Saykin et al., 1994; Weinberger and Gallhofer, 1997; Heckers et al., 1998; Wood et al., 2002; Bertolino et al., 2003; Egeland et al., 2003; Brewer et al., 2005; Bartholomeusz et al., 2011). In contrast with the PPI studies, the atypical antipsychotics, clozapine and aripiprazole, but not haloperidol, showed an enhancement of efficacy by BQCA in reversing MK-801–induced spatial memory disruption in the Y-maze. The hippocampus has a high expression of M_1 mAChRs, which are important for memory formation in rodents (Talts et al., 1998; Anagnostaras et al., 2003; Lee and Kesner, 2003; Newell et al., 2007; Mauck et al., 2010; Peng et al., 2012). Indeed, BQCA enhances baseline spatial and object recognition memory in rodents (Chambon et al., 2011, 2012), reverses scopolamine-disrupted fear and working memory, and restores memory function in Tg2576 mice (Ma et al., 2009; Shirey et al., 2009; Chambon et al., 2012). To our knowledge, however, ours is the first study to extend these effects to rescue of MK-801–induced memory impairments, albeit in the presence of a coadministered antipsychotic. Interestingly, another recent study showed that a PAM of the M_4 mAChR subtype could rescue MK-801–induced impairments in a touchscreen-based memory retrieval task (Bubser et al., 2014), and earlier work established that the cholinesterase inhibitor, donepezil, can also rescue MK-801–disrupted fear memory (Csernansky et al., 2005).

In terms of the brain regions mediating the interactions between the M_1 mAChR PAM and antipsychotics in our models, it is likely that cortical and striatal regions are involved in the PPI effects, since they express the M_1 mAChR (Han et al., 2008; Ma et al., 2009; Peng et al., 2012) and have been implicated in regulation of sensorimotor gating mechanisms (Swerdlow et al., 1990, 2001; Geyer et al., 2001; Braff, 2010). Although the M_1 mAChR is also found in the hippocampus, it is unlikely to be as important in the observed effects, as MK-801–induced PPI disruption does not involve this region and, if anything, cholinergic activation in the hippocampus can itself lead to some PPI disruption (Caine et al., 1991, 1992; Zhang et al., 2000). In contrast, the Y-maze test is substantially hippocampal dependent (Conrad et al., 1996, 2007; Choy et al., 2010; Shipton et al., 2014). Nonetheless, the possible involvement of cortical regions in both behaviors should not be overlooked, as cortical, striatal, and

hippocampal networks play an important role in higher cognitive function (Turnock and Becker, 2008; Pennartz et al., 2011; Britt et al., 2012).

An area of ongoing discussion is the issue of whether "single-target bullets" or "multifunction drugs" will lead to more effective medications for schizophrenia (Pantelis and Barnes, 1996; Roth et al., 2004; Miyamoto et al., 2012). What remains indisputable, however, is that schizophrenia is a disorder that requires drugs capable of targeting multiple symptom domains, in particular cognitive deficits. Moreover, the incidence of adverse effects remains a major problem for patients undergoing chronic treatment with existing antipsychotics (Nasrallah, 2008). Both of these issues may conceivably be addressed by judicious combination therapies. For instance, although clozapine was used as proof of concept in our study, it may not be amenable for combination therapies in practice due to its known on-target mAChR effects, whereas other atypical agents (e.g., aripiprazole or risperidone, which have minimal mAChR activity; Roth et al., 2004) may represent more appropriate candidates. Furthermore, the addition of a highly selective mAChR PAM (i.e., single-target bullet) may yield an increase in symptom domain coverage together with an existing antipsychotic (i.e., multifunction drug). Although these issues remain speculative at this time, our study shows that we can observe synergistic or additive efficacy in our models while essentially retaining normal exploratory behaviors in the Y-maze test and normal body reflex upon acoustic startle stimulation in the PPI test. Thus, in addition to offering novel approaches to targeting G protein–coupled receptors in a highly selective manner to address unmet medical needs, allosteric modulators may potentially allow extension of the clinical efficacy of existing therapeutics and warrant further study in this regard.

Authorship Contributions

Participated in research design: Choy, Shackleford, Malone, Lane, Christopoulos.

Conducted experiments: Choy, Shackleford, Mistry, Patil, Scammells, Lane.

Performed data analysis: Choy, Shackleford, Malone, Lane.

Wrote or contributed to the writing of the manuscript: Choy, Shackleford, Malone, Mistry, Scammells, Langmead, Pantelis, Sexton, Lane, Christopoulos.

References

Abdul-Ridha A, Lane JR, Mistry SN, López L, Sexton PM, Scammells PJ, Christopoulos A, and Canals M (2014) Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor. *J Biol Chem* **289**: 33701–33711.

Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, and Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. *Nat Neurosci* **6**:51–58.

Bakshi VP, Swerdlow NR, and Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. *J Pharmacol Exp Ther* **271**:787–794.

Barak S and Weiner I (2011) The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. *Int J Neuropsychopharmacol* **14**:1233–1246.

Bartholomeusz CF, Proffitt TM, Savage G, Simpson L, Markulev C, Kerr M, McConchie M, McGorry PD, Pantelis C, Berger GE, et al. (2011) Relational memory in first episode psychosis: implications for progressive hippocampal dysfunction after illness onset. *Aust N Z J Psychiatry* **45**:206–213.

Bast T, Zhang W, Feldon J, and White IM (2000) Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. *Pharmacol Biochem Behav* **67**:647–658.

Bertolino A, Sciota D, Brudaglio F, Altamura M, Blasi G, Bellomo A, Antonucci N, Callicott JH, Goldberg TE, Scarabino T, et al. (2003) Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. *Am J Psychiatry* **160**:483–489.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. *Arch Neurol* **54**:465–473.

Bolbecker AR and Shekhar A (2012) Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions. *Handb Exp Pharmacol* **208**:167–190.

Bora E, Yucel M, and Pantelis C (2009) Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. *Br J Psychiatry* **195**:475–482.

Bradford AM, Savage KM, Jones DN, and Kalinichev M (2010) Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. *Psychopharmacology (Berl)* **212**:155–170.

Braff DL (2010) Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. *Curr Top Behav Neurosci* **4**:349–371.

Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, and McGorry PD (2005) Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. *Am J Psychiatry* **162**:71–78.

Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, and Lindsley CW (2010) The antipsychotic potential of muscarinic allosteric modulation. *Drug News Perspect* **23**:229–240.

Britt JP, Benaliouad F, McDevitt RA, Stuber GD, Wise RA, and Bonci A (2012) Synaptic and behavioral profile of multiple glutamatergic inputs to the nucleus accumbens. *Neuron* **76**:790–803.

Bubeníková V, Votava M, Horácek J, Pálenícek T, and Dockery C (2005) The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. *Pharmacol Biochem Behav* **80**:591–596.

Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, Lamsal A, Niswender CM, Daniels JS, Poslusney MS, et al. (2014) Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairment and enhances associative learning in rodents. *ACS Chem Neurosci* **5**:920–942.

Bymaster FP, Felder C, Ahmed S, and McKinzie D (2002) Muscarinic receptors as a target for drugs treating schizophrenia. *Curr Drug Targets CNS Neurol Disord* **1**:163–181.

Bymaster FP, McKinzie DL, Felder CC, and Wess J (2003) Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. *Neurochem Res* **28**:437–442.

Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, and Calligaro DO (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. *Schizophr Res* **37**:107–122.

Cadenhead KS, Carasso BS, Swerdlow NR, Geyer MA, and Braff DL (1999) Prepulse inhibition and habituation of the startle response are stable neurobiological measures in a normal male population. *Biol Psychiatry* **45**:360–364.

Caine SB, Geyer MA, and Swerdlow NR (1991) Carbachol infusion into the dentate gyrus disrupts sensorimotor gating of startle in the rat. *Psychopharmacology (Berl)* **105**:347–354.

Caine SB, Geyer MA, and Swerdlow NR (1992) Hippocampal modulation of acoustic startle and prepulse inhibition in the rat. *Pharmacol Biochem Behav* **43**:1201–1208.

Canals M, Lane JR, Wen A, Scammells PJ, Sexton PM, and Christopoulos A (2012) A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. *J Biol Chem* **287**:650–659.

Chambon C, Jatzke C, Wegener N, Gravius A, and Danysz W (2012) Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication. *Eur J Pharmacol* **697**:73–80.

Chambon C, Wegener N, Gravius A, and Danysz W (2011) A new automated method to assess the rat recognition memory: validation of the method. *Behav Brain Res* **222**:151–157.

Choy KH, de Visser Y, Nichols NR, and van den Buuse M (2008) Combined neonatal stress and young-adult glucocorticoid stimulation in rats reduce BDNF expression in hippocampus: effects on learning and memory. *Hippocampus* **18**:655–667.

Choy KH, Dean O, Berk M, Bush AI, and van den Buuse M (2010) Effects of N-acetylcysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. *Eur J Pharmacol* **649**:224–228.

Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. *Nat Rev Drug Discov* **1**:198–210.

Conn PJ, Lindsley CW, Meiler J, and Niswender CM (2014) Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. *Nat Rev Drug Discov* **13**:692–708.

Conn PJ, Tamminga C, Schoepp DD, and Lindsley C (2008) Schizophrenia: moving beyond monoamine antagonists. *Mol Interv* **8**:99–107.

Conrad CD, Galea LA, Kuroda Y, and McEwen BS (1996) Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. *Behav Neurosci* **110**:1321–1334.

Conrad CD, Lupien SJ, Thanasoulis LC, and McEwen BS (1997) The effects of type I and type II corticosteroid receptor agonists on exploratory behavior and spatial memory in the Y-maze. *Brain Res* **759**:76–83.

Conrad CD, McLaughlin KJ, Harman JS, Foltz C, Wieczorek L, Lightner E, and Wright RL (2007) Chronic glucocorticoids increase hippocampal vulnerability

to neurotoxicity under conditions that produce CA3 dendritic retraction but fail to impair spatial recognition memory. *J Neurosci* **27**:8278–8285.

Csernansky JG, Martin M, Shah R, Bertchume A, Colvin J, and Dong H (2005) Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. *Neuropsychopharmacology* **30**:2135–2143.

Cui YH, Zheng Y, Yang YP, Liu J, and Li J (2010) Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: a pilot study in China. *J Child Adolesc Psychopharmacol* **20**:291–298.

Dellu F, Mayo W, Cherkaoui J, Le Moal M, and Simon H (1992) A two-trial memory task with automated recording: study in young and aged rats. *Brain Res* **588**:132–139.

Didriksen M, Kreilgaard M, and Arnt J (2006) Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. *Eur J Pharmacol* **542**:108–115.

Egeland J, Sundet K, Rund BR, Asbjørnsen A, Hugdahl K, Landrø NI, Lund A, Roness A, and Stordal KI (2003) Sensitivity and specificity of memory dysfunction in schizophrenia: a comparison with major depression. *J Clin Exp Neuropsychol* **25**:79–93.

Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, and Ito A (2008) Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. *Behav Brain Res* **186**:197–207.

Galloway CR, Lebois EP, Shagarabi SL, Hernandez NA, and Manns JR (2014) Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats. *Pharmacology* **93**:57–64.

Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, and Calabrese JR (2008) Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. *J Clin Psychopharmacol* **28**:203–209.

Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, and Tonegawa S (2001) Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. *Proc Natl Acad Sci USA* **98**:15312–15317.

Geyer MA, Krebs-Thomson K, Braff DL, and Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. *Psychopharmacology (Berl)* **156**:117–154.

Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, Talpos J, and Tricklebank M (2012) NMDA receptors, cognition and schizophrenia–testing the validity of the NMDA receptor hypofunction hypothesis. *Neuropharmacology* **62**:1401–1412.

Gordon JA (2010) Testing the glutamate hypothesis of schizophrenia. *Nat Neurosci* **13**:2–4.

Gould RW, Dencker D, Grannan M, Bubser M, Zhan X, Wess J, Xiang Z, Locuson C, Lindsley CW, Conn PJ, et al. (2015) Role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice. *ACS Chem Neurosci* **6**:1683–1695.

Gronier B, Perry KW, and Rasmussen K (2000) Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area. *Psychopharmacology (Berl)* **147**:347–355.

Grube BS, Bilder RM, and Goldman RS (1998) Meta-analysis of symptom factors in schizophrenia. *Schizophr Res* **31**:113–120.

Han M, Newell K, Zavitsanou K, Deng C, and Huang XF (2008) Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. *J Neurosci* **86**:457–464.

Harrison PJ (2004) The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. *Psychopharmacology (Berl)* **174**:151–162.

Harrison PJ and Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. *Mol Psychiatry* **10**:40–68; image 45.

Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, and Davis KL (1998) Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. *Am J Psychiatry* **155**:1080–1086.

Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ, and Alpert NM (1998) Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. *Nat Neurosci* **1**:318–323.

Heinrichs RW and Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology* **12**:426–445.

Ishii D, Matsuzawa D, Kanahara N, Matsuda S, Sutoh C, Ohtsuka H, Nakazawa K, Kohno M, Hashimoto K, Iyo M, et al. (2010) Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. *Neurosci Lett* **471**:53–57.

Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. *Int Rev Neurobiol* **78**:69–108.

Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. *Am J Psychiatry* **148**:1301–1308.

Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, et al. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. *J Neurosci* **28**:10422–10433.

Kandel ER (2000) Disorders of thought and volition: schizophrenia, in *Principles of Neural Science* (Kandel ER, Schwartz JH, and Jessell TM eds) p 1414, McGraw-Hill, New York.

Kapur S, VanderSpek SC, Brownlee BA, and Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. *J Pharmacol Exp Ther* **305**:625–631.

Katsnelson A (2014) Drug development: The modelling challenge. *Nature* **508**:S8–S9.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, et al.; CATIE Investigators; Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in

patients with chronic schizophrenia in the CATIE Trial. *Arch Gen Psychiatry* **64**: 633–647.

Keith VA, Mansbach RS, and Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. *Biol Psychiatry* **30**:557–566.

Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, and Wess J (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. *Nat Rev Drug Discov* **13**:549–560.

Langmead CJ, Watson J, and Reavill C (2008) Muscarinic acetylcholine receptors as CNS drug targets. *Pharmacol Ther* **117**:232–243.

Lee I and Kesner RP (2003) Time-dependent relationship between the dorsal hippocampus and the prefrontal cortex in spatial memory. *J Neurosci* **23**: 1517–1523.

Lester DB, Rogers TD, and Blaha CD (2010) Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. *CNS Neurosci Ther* **16**: 137–162.

Lieberman JA, Javitch JA, and Moore H (2008) Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. *Am J Psychiatry* **165**:931–936.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* **353**: 1209–1223.

Lipska BK and Weinberger DR (2002) A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. *Neurotox Res* **4**:469–475.

Long LE, Malone DT, and Taylor DA (2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. *Neuropsychopharmacology* **31**: 795–803.

Lublin H, Eberhard J, and Levander S (2005) Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. *Int Clin Psychopharmacol* **20**:183–198.

Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, et al. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. *Proc Natl Acad Sci USA* **106**:15950–15955.

Mansbach RS, Geyer MA, and Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. *Psychopharmacology (Berl)* **94**:507–514.

Matsuo N, Takao K, Nakanishi K, Yamasaki N, Tanda K, and Miyakawa T (2010) Behavioral profiles of three C57BL/6 substrains. *Front Behav Neurosci* **4**:29.

Mauck B, Lucot JB, Paton S, and Grubbs RD (2010) Cholinesterase inhibitors and stress: effects on brain muscarinic receptor density in mice. *Neurotoxicology* **31**: 461–467.

Miyamoto S, Duncan GE, Marx CE, and Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Mol Psychiatry* **10**:79–104.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, and Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. *Mol Psychiatry* **17**: 1206–1227.

Moghaddam B and Javitt D (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. *Neuropsychopharmacology* **37**:4–15.

Moore H, Geyer MA, Carter CS, and Barch DM (2013) Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. *Neurosci Biobehav Rev* **37** (Pt B):2087–2091.

Murray JB (2002) Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. *J Psychol* **136**:319–327.

Mutlu O, Ulak G, Celikyurt IK, Akar FY, and Erden F (2011) Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. *Pharmacol Biochem Behav* **98**:398–404.

Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. *Mol Psychiatry* **13**:27–35.

Natesan S, Reckless GE, Barlow KB, Nobrega JN, and Kapur S (2011) Partial agonists in schizophrenia–why some work and others do not: insights from preclinical animal models. *Int J Neuropsychopharmacol* **14**:1165–1178.

Newell KA, Zavitsanou K, and Huang XF (2007) Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. *J Neurosci Res* **85**:1358–1363.

Nicolazzo JA, Steuten JA, Charman SA, Taylor N, Davies PJ, and Petrou S (2010) Brain uptake of diazepam and phenytoin in a genetic animal model of absence epilepsy. *Clin Exp Pharmacol Physiol* **37**:647–649.

Nilsson M, Hansson S, Carlsson A, and Carlsson ML (2007) Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice. *Neuroscience* **149**:123–130.

Owen MJ, Sawa A, and Mortensen PB (2016) Schizophrenia. *Lancet* **388**:86–97.

Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, and Robbins TW (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. *Schizophr Res* **37**:251–270.

Pantelis C and Barnes TR (1996) Drug strategies and treatment-resistant schizophrenia. *Aust N Z J Psychiatry* **30**:20–37.

Pantelis C, Barnes TR, Nelson HE, Tanner S, Weatherley L, Owen AM, and Robbins TW (1997) Frontal-striatal cognitive deficits in patients with chronic schizophrenia. *Brain* **120**:1823–1843.

Pantelis C and Lambert TJ (2003) Managing patients with "treatment-resistant" schizophrenia. *Med J Aust* **178** (Suppl):S62–S66.

Pantelis C, Stuart GW, Nelson HE, Robbins TW, and Barnes TR (2001) Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. *Am J Psychiatry* **158**:1276–1285.

Park SJ, Lee Y, Oh HK, Lee HE, Lee Y, Ko SY, Kim B, Cheong JH, Shin CY, and Ryu JH (2014) Oleanolic acid attenuates MK-801-induced schizophrenia-like behaviors in mice. *Neuropharmacology* **86**:49–56.

Peng S, Zhang Y, Li GJ, Zhang DX, Sun DP, and Fang Q (2012) The effect of sevoflurane on the expression of M1 acetylcholine receptor in the hippocampus and cognitive function of aged rats. *Mol Cell Biochem* **361**:229–233.

Pennartz CM, Ito R, Verschure PF, Battaglia FP, and Robbins TW (2011) The hippocampal-striatal axis in learning, prediction and goal-directed behavior. *Trends Neurosci* **34**:548–559.

Porter AC, Bymaster FP, DeLapp NW, Yamada M, Wess J, Hamilton SE, Nathanson NM, and Felder CC (2002) M1 muscarinic receptor signaling in mouse hippocampus and cortex. *Brain Res* **944**:82–89.

Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. *Nat Rev Drug Discov* **3**:353–359.

Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, Giegling I, Genius J, McCarley RW, Möller HJ, et al. (2006) A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. *Biol Psychiatry* **59**: 721–729.

Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, et al. (2013) Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. *Schizophr Bull* **39**: 564–574.

Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, and Gur RC (1994) Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. *Arch Gen Psychiatry* **51**:124–131.

Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, and Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. *Am J Psychiatry* **165**: 1033–1039.

Shipton OA, El-Gaby M, Apergis-Schoute J, Deisseroth K, Bannerman DM, Paulsen O, and Kohl MM (2014) Left-right dissociation of hippocampal memory processes in mice. *Proc Natl Acad Sci USA* **111**:15238–15243.

Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, et al. (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. *J Neurosci* **29**: 14271–14286.

Speller JC, Barnes TR, Curson DA, Pantelis C, and Alberts JL (1997) One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. *Br J Psychiatry* **171**: 564–568.

Stone JM, Morrison PD, and Pilowsky LS (2007) Glutamate and dopamine dysregulation in schizophrenia–a synthesis and selective review. *J Psychopharmacol* **21**: 440–452.

Suratman S, Leach K, Sexton P, Felder C, Loiacono R, and Christopoulos A (2011) Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. *Br J Pharmacol* **162**:1659–1670.

Sweatt JD (2004) Hippocampal function in cognition. *Psychopharmacology (Berl)* **174**:99–110.

Swerdlow NR, Braff DL, and Geyer MA (1990) GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. *Brain Res* **532**:146–150.

Swerdlow NR, Braff DL, Taaid N, and Geyer MA (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. *Arch Gen Psychiatry* **51**:139–154.

Swerdlow NR and Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. *Schizophr Bull* **24**:285–301.

Swerdlow NR, Geyer MA, and Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. *Psychopharmacology (Berl)* **156**:194–215.

Talts U, Talts JF, and Eriksson P (1998) Differential expression of muscarinic subtype mRNAs after exposure to neurotoxic pesticides. *Neurobiol Aging* **19**: 553–559.

Tanskanen P, Veijola JM, Piippo UK, Haapea M, Miettunen JA, Pyhtinen J, Bullmore ET, Jones PB, and Isohanni MK (2005) Hippocampus and amygdala volumes in schizophrenia and other psychoses in the Northern Finland 1966 birth cohort. *Schizophr Res* **75**:283–294.

Thal DM, Sun B, Feng D, Nawaratne V, Leach K, Felder CC, Bures MG, Evans DA, Weis WI, Bachhawat P, et al. (2016) Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. *Nature* **531**:335–340.

Thomsen M, Wess J, Fulton BS, Fink-Jensen A, and Caine SB (2010) Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice. *Psychopharmacology (Berl)* **208**:401–416.

Turnock M and Becker S (2008) A neural network model of hippocampal-striatal-prefrontal interactions in contextual conditioning. *Brain Res* **1202**: 87–98.

Vakalopoulos C (2006) Neuropharmacology of cognition and memory: a unifying theory of neuromodulator imbalance in psychiatry and amnesia. *Med Hypotheses* **66**:394–431.

van der Staay FJ, Rutten K, Erb C, and Blokland A (2011) Effects of the cognition impairer MK-801 on learning and memory in mice and rats. *Behav Brain Res* **220**: 215–229.

van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, Agartz I, Westlye LT, Haukvik UK, Dale AM, et al. (2016) Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol Psychiatry* **21**:547–553.

van Erp TG, Saleh PA, Huttunen M, Lönnqvist J, Kaprio J, Salonen O, Valanne L, Poutanen VP, Standertskjöld-Nordenstam CG, and Cannon TD (2004) Hippocampal volumes in schizophrenic twins. *Arch Gen Psychiatry* **61**:346–353.

Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, Smith D, Brewer W, Proffitt T, Desmond P, et al. (2006) Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. *Arch Gen Psychiatry* **63**:139–149.

Weinberger DR (1999) Cell biology of the hippocampal formation in schizophrenia. *Biol Psychiatry* **45**:395–402.

Weinberger DR and Gallhofer B (1997) Cognitive function in schizophrenia. *Int Clin Psychopharmacol* **12** (Suppl 4):S29–S36.

Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, and Middlemiss DN (1999) Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. *Br J Pharmacol* **126**:1620–1624.

Wood SJ, Pantelis C, Proffitt T, Phillips LJ, Stuart GW, Buchanan JA, Mahony K, Brewer W, Smith DJ, and McGorry PD (2003) Spatial working memory ability is a marker of risk-for-psychosis. *Psychol Med* **33**:1239–1247.

Wood SJ, Proffitt T, Mahony K, Smith DJ, Buchanan JA, Brewer W, Stuart GW, Velakoulis D, McGorry PD, and Pantelis C (2002) Visuospatial memory and learning in first-episode schizophreniform psychosis and established schizophrenia: a functional correlate of hippocampal pathology? *Psychol Med* **32**:429–438.

Yee BK, Chang T, Pietropaolo S, and Feldon J (2005) The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. *Behav Brain Res* **163**:265–276.

Young JW, Zhou X, and Geyer MA (2010) Animal models of schizophrenia. *Curr Top Behav Neurosci* **4**:391–433.

Zhang WN, Bast T, and Feldon J (2000) Microinfusion of the non-competitive N-methyl-D-aspartate receptor antagonist MK-801 (dizocilpine) into the dorsal hippocampus of Wistar rats does not affect latent inhibition and prepulse inhibition, but increases startle reaction and locomotor activity. *Neuroscience* **101**:589–599.

Address correspondence to: Arthur Christopoulos or J. Robert Lane, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia. E-mail: arthur.christopoulos@monash.edu or rob.lane@monash.edu

1   **SUPPLEMENTAL DATA**

2

3   **Title: Positive allosteric modulation of the muscarinic M$_1$ receptor improves efficacy of**

4   **antipsychotics in mouse glutamatergic deficit models of behavior**

5

6

7   **Authors:** Kwok H. C. Choy, David M. Shackleford, Daniel T. Malone, Shailesh N. Mistry,

8   Rahul T. Patil, Peter J. Scammells, Christopher J. Langmead, Christos Pantelis, Patrick M.

9   Sexton, Johnathan R. Lane and Arthur Christopoulos

10

1

2

3

1 **Supplemental Fig.1**
2
3 **Startle amplitude measured at pulse alone (p100, 110 and 120) during the PPI test**
4 **remained unaffected by drug pretreatment, except mice that were treated by 20 mg/kg**
5 **(s.c.) of BQCA and MK-801 (0.3 mg/kg).** In particular, the higher startle amplitude is
6 observed in tested mice measured at 110 and 120db stimulus (top panel).
7 Data are mean ± SEM, * $p < 0.05$ vs MK-801 control, and [#] $p < 0.05$ vs vehicle control (-----).
8

Supplemental Fig. 2.

PPI measured at p100 and p110 exhibited a similar effect as observed at p120. As mentioned in Materials and Methods, mice were tested in PPI of startle elicited by acoustic stimulus of 100, 110 and 120db, and prepulses. PPI measured at 120db is presented in the main text. PPI measured at p100 and p110 either shared a similar reversal seen in p120 or a trend of reversal, by combination of BQCA and antipsychotics.

4

1   Data are mean $\pm$ SEM, $^{\wedge}p < 0.05$ for difference between vehicle vs MK-801 controls, as

2   indication of PPI disruption by MK-801; * $p < 0.05$ for difference between groups vs. MK-

3   801 control for a significant reversal of PPI disruption.

left bar – novel arm "N"
right bar – familiar arm

1

2

3 **Supplemental Fig. 3.**

4

5 **Memory function was not affected by pretreatment of BQCA alone, or combined BQCA**
6 **and antipsychotics treatment, in mice without MK-801 treatment**, whereas C57Bl/6J
7 mice received BQCA (10 mg/kg s.c.) and clozapine (1 mg/kg), or aripiprazole (0.25 mg/kg)
8 exhibited insufficient exploratory activity, and therefore excluded.
9 * $p < 0.05$ for difference between novel and familiar arm as an indication of normal memory
10 function.
11

1
2

3
4
5

6 **Supplemental Fig 4.**

7

8 **Assessment of BQCA exposure in mouse brain in the absence or presence of**
9 **antipsychotics.** (a) *Experiment 1*: Unbound concentrations ($C_{unbound}$ in nM) of BQCA in
10 brains of C57Bl/6J mice after s.c. (Suspensions in 50% Pharmasolve® based vehicle) or i.p.

1   (Solutions in 15% DMSO based vehicle) injection. I.p. injection of BQCA resulted in a
2   higher drug delivery to the brain than s.c. injection. (b) *Experiment 2*: $C_{unbound}$ of BQCA in
3    $M_1^{+/+}$ and $M_1^{-/-}$ mice (C57Bl/6N background) compared to C57Bl/6J mice, suggests that
4   BQCA brain exposure was lower in the C57Bl/6N mice than C57Bl/6J mice, and that there
5   was no difference between the genotypes ($M_1^{+/+}$ vs. $M_1^{-/-}$). (c) *Experiment 3*: $C_{unbound}$ of
6   BQCA in brain was assessed in C57Bl/6J mice after s.c. injection of BQCA (20 mg/kg), with
7   or without coadministration of haloperidol (0.25 mg/kg i.p.), clozapine (2 mg/kg i.p.) or
8   aripiprazole (top left graph). C_{total} of the antipsychotics (haloperidol, clozapine or aripiprazole)
9   in brain was also assessed with or without coadministration of BQCA (20 mg/kg s.c.) (top
10   right and bottom graphs). There was no enhancement of brain exposure of BQCA or
11   antipsychotics when mice were dosed with both compounds.
12
13   $C_{unbound}$ was calculated as $C_{total} * f_u$ using published f_u values of 0.126 in brain, respectively
14   (Gould et al., 2015). Each value represents the mean within the range of data of *n = 2-3*
15   animals per group.

Route of administration			s.c.	s.c.	s.c.		i.p.	i.p.	i.p.
Injection dose (mg/kg)			3	10	20		0.1	1	20
nM @ 45min			22.5	30.7	36.0		na	39.1	477.4

1

2

3 **Supplemental Fig. 5.**

4

5 **Reversal of disrupted PPI induced by MK-801 in C57Bl/6J mice receiving BQCA via i.p.**
6 **administration using a lower dosing range,** as BQCA administered via .i.p. route (DMSO
7 containing vehicle) allowed a higher brain exposure compared to s.c. route. There was a
8 similar $C_{unbound}$ (in nM) of BQCA in the brain observed between BQCA administrated via i.p.
9 and s.c. (39.1 ± 4.6 nM and 36.0 ± 4.5 nM respectively). Furthermore, a high dose of BQCA
10 via i.p. (20 mg/kg) also produced a similar reversal effect on MK-801 treatment.

11

12 Methods and data analysis: A separated cohort of C57Bl/6J received BQCA via i.p. route,
13 together with vehicle and MK-801 alone controls. For data analysis, this PPI data was
14 combined with data obtained from BQCA (s.c.) + clozapine cohort (Fig. 3b). The PPI% of
15 both vehicle groups were approximately the same: BQCA s.c. cohort = $36.7 \pm 2.5\%$ and
16 BQCA i.p. cohort = $36.9 \pm 3.2\%$. ANOVA test were performed on the combined PPI data.
17 BQCA ($p < 0.001$), clozapine ($p = 0.022$) and MK-801 ($p < 0.001$) effects were found, and
18 then followed with Tukey's post hoc comparisons, where ^ $p < 0.05$ for significant PPI
19 disruptive effect of MK-801, and * $p < 0.05$ for difference with MK-801.
20